Gossamer Bio(US:GOSS) TMX Newsfile·2026-03-16 04:12Group 1 - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company's lead pipeline candidate, Seralutinib, was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2] - During the Q1 2025 earnings call, the CEO expressed optimism about the trial's results, stating that the baseline characteristics were targeted and that there was "over 90% power given the sample size," although the primary efficacy endpoint did not achieve statistical significance [3] Group 2 - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5]